Title: Supplementum 251: Abstracts of the annual congress of the Swiss Society for Allergology and Immunology, August 19-20, 2021
Abstract: Drug rash with eosinophilia and systemic symptoms (DRESS) is a rare severe drug hypersensitivity reaction.Treatment of DRESS currently consists of systemic corticosteroids.Here, we report benralizumab (Fasenra ® ) as a treatment for corticosteroid-refractory DRESS occurring in two severely ill COVID-19 patients.Both patients received high-dose intravenous corticosteroids for 4-6 days, but cutaneous symptoms, eosinophilia and signs of related organ damage were deteriorating.Based on its successful use in PDGFRA-independent hypereosinophilia, we decided to treat our patients with benralizumab.The patients showed clinical improvement and a rapid substantial drop in eosinophils.Targeted high-throughput serum proteomics prior vs. after treatment revealed a significant reduction mostly in eosinophil-and T cell response-related proteins (a.e.IL-5, CD8, TNF and PD-L1), thus pointing towards an impact of benralizumab on the (drug-directed) T cell response in DRESS. P2